Tumors, which often exhibit heightened PARP activity, rely on timely PAR turnover, so cancers with replication stress or HR defects may be vulnerable to PARG inhibitors, as PAR accumulation at forks can precipitate fork collapse [178]. The gene discussed is PARP1; the disease is cancer.